1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Glaukos Corporation

Glaukos Corporation

GKOS
Glaukos CorporationUS flagNew York Stock Exchange
165.60
USD
-2.29
- -
9.77BMarket Cap
Glaukos Corporation
GKOS
(New York Stock Exchange)

Recent

price

165.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.84
1.83
4.1
3.47
4.63
5.13
6.34
5.06
6.33
5.96
6.5
7.27
8.87
10.58
Revenue per Share
-0.51
-0.49
-2.13
0.14
- -
-0.37
0.41
-2.7
-1.07
-2.09
-2.78
-2.77
-3.28
-3.25
Basic EPS, GAAP
-0.57
-0.32
-0.18
0.18
0.58
0.24
-0.14
-0.67
-0.5
-1.34
-1.61
-1.28
-0.68
-0.5
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-10.02
-5.09
2.96
3.46
3.99
4.82
15.48
14.75
12.5
11.1
9.4
13.59
11.41
11.6
Book Value per Share
-10.59
-5.55
2.64
3.26
3.9
4.82
5.16
5.38
4.01
3.27
2.29
7.75
7.78
8.3
Tangible Book Value per Share
25
25
17
33
34
35
37
44
46
47
48
53
57
58
Basic Weighted Avg Shares
21
46
72
114
159
181
237
225
294
283
315
383
507
613
Sales/Revenue/Turnover
-67.78
-28.89
-14.36
3.71
1.91
-7.17
-19.64
-54.92
-17.98
-36.17
-39.31
-28.2
-39.33
-31.31
Operating Margin (%)
1
4
4
5
5
6
10
35
34
36
38
40
42
46
Depreciation Expense
-13
-12
-37
5
- -
-13
15
-120
-50
-99
-135
-146
-188
-188
Net Income, GAAP
- -
- -
- -
0.94
9,300
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-60.34
-26.6
-51.94
3.95
-0.06
-7.14
6.51
-53.5
-16.87
-35.07
-42.79
-38.17
-36.99
-30.68
Profit Margin (%)
6
-10
84
103
123
146
205
420
423
372
321
375
374
413
Working Capital
18
9
1
- -
- -
- -
73
271
382
382
384
103
104
103
LT Debt
-149
-161
95
117
138
174
673
667
587
530
462
767
656
682
Total Equity
- -
- -
- -
3.79
-219.81
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
4.61
-0.07
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
4.26
-0.07
-8.3
3.64
-17.95
-7.91
-17.76
-27.16
-23.83
-26.38
-25.98
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
104
103
103
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
59
Market Capitalization
6,494
6,283
8,226

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
475
486
516
Cash, Cash Equivalents & STI
279
277
286
Accounts Receivable, Net
109
120
139
Inventories
64
62
59
Total Current Liabilities
101
89
102
Payables & Accruals
73
76
81
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
37.03%
3.4%
-14.44%
Free Cash Flow
32.16%
23.84%
-42.23%
Net Income, GAAP
1,277.75%
22.78%
28.23%
Sales/Revenue/Turnover
23.06%
18.47%
32.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
86
96
97
105
383
2025
107
124
134
143
507
2026
151
186
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.82
-1
-0.39
-0.6
-2.77
2025
-0.32
-0.34
-0.28
-2.32
-3.28
2026
-0.34
-0.31
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Accuray Incorporated (0H8I.L)
Therma Bright Inc. (THRM.V)
Stryker Corporation (SYK.TO)
Inspira Technologies Oxy B.H.N. Ltd. (IINNW)
Taiwan Biomaterial Co., Ltd. (6649.TWO)
Siemens Healthineers AG (0PMJ.L)
Business
Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Founded in 1998 and headquartered in Aliso Viejo, California, Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) technology, launching the first MIGS device commercially in 2012. Its core products include the iStent family of micro-scale surgical devices to reduce intraocular pressure in glaucoma patients; the iDose TR, a first-of-its-kind, long-duration intracameral procedural pharmaceutical implant delivering continuous glaucoma drug therapy inside the eye; a proprietary, FDA-approved corneal cross-linking therapy for keratoconus; transdermal pharmaceuticals for treating glaucoma, dry eye, presbyopia, and ocular surface diseases; and bio-erodible sustained-release drug delivery implants for retinal diseases. The company operates globally with locations in the United States, Canada, the United Kingdom, Germany, Japan, Australia, and Brazil. Recent major developments include the commercial launch of the iDose TR implant in 2024, which delivers sustained glaucoma drug therapy, marking a significant advancement in dropless therapies. In 2025, Glaukos reported record net sales with notable growth in glaucoma product sales, raised full-year 2025 revenue guidance to $490 million to $495 million, and issued preliminary 2026 sales guidance of $600 million to $620 million. The company also received FDA approval for a new eye therapy named Epioxa, expected to be commercially available in early 2026. Glaukos continues to invest in expanding its pipeline of novel dropless platform technologies aimed at improving patient outcomes and advancing the standard of care across its ophthalmic focus areas. It maintains a strong financial position with no debt and substantial cash reserves as of the third quarter of 2025. Glaukos' shares trade on the New York Stock Exchange under the ticker symbol GKOS.

Company News

Company News APIChatGPT

  • zacks.com

    Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

  • seekingalpha.com

    Glaukos: The Second J-Code Rewrites The Risk Math

  • zacks.com

    Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

  • benzinga.com

    Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

  • businesswire.com

    Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

  • benzinga.com

    Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

  • businesswire.com

    Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

  • reuters.com

    Glaukos says late-stage eye disease treatment shows lasting benefits after single dose

  • businesswire.com

    Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

  • businesswire.com

    Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

  • zacks.com

    Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

  • businesswire.com

    Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus

  • defenseworld.net

    Glaukos Corporation $GKOS Shares Sold by Squarepoint Ops LLC

  • defenseworld.net

    Corient Private Wealth LP Takes Position in Glaukos Corporation $GKOS

  • zacks.com

    Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?

  • defenseworld.net

    Glaukos Corporation $GKOS Stock Holdings Trimmed by Algert Global LLC

  • defenseworld.net

    61,957 Shares in Glaukos Corporation $GKOS Purchased by Deutsche Bank AG

  • zacks.com

    GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

  • zacks.com

    Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now

  • businesswire.com

    Glaukos Announces Participation in Wells Fargo Healthcare Conference